A newer edition of this regulation is available: January 2021

Volleyball·

FIVB Medical & Anti-Doping Regulations - January 2017 edition

SupersededJanuary 2017
Adopted
2014/10/29

The 2017 edition of the FIVB Medical and Anti-Doping Regulations; the oldest version available in this collection.

PublicationFédération Internationale de Volleyball — 2017 edition
StructureMedical and Anti-Doping Regulations, 2017 edition
StatusSuperseded — replaced by the January 2021 version

What are the Volleyball Medical and Anti-Doping Regulations?

The Medical and Anti-Doping Regulations of the Fédération Internationale de Volleyball (FIVB) bring two documents together in a single text: the medical rules for events — including the injury reporting procedure — and the anti-doping rules, which implement the World Anti-Doping Code in volleyball. The Federation may delegate part or all of doping control to a third party such as the International Testing Agency (ITA), and results management and adjudication to the Anti-Doping Division of the Court of Arbitration for Sport, but responsibility for compliance remains its own.

About the January 2017 version

Features of this version

  1. Two areas in one documentThe text brings together the medical rules for events and the anti-doping rules in one place.

Who this document matters to

Every doping case involving a volleyball player is decided on the basis of this text. The decisive point in a defence: liability is strict, and establishing a violation requires no proof of intent, fault or negligence on the athlete's part. The medical regulations are likewise binding on the team physician and the federation at international events.